Tot Biopharm International Co Sustainability Profile
Tot Biopharm International Co., a leading player in the biopharmaceutical industry, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2016, the company has rapidly established itself as a key innovator in the development of high-quality biopharmaceutical products, particularly in the fields of oncology and autoimmune diseases. With a robust portfolio that includes monoclonal antibodies and biosimilars, Tot Biopharm distinguishes itself through its commitment to advanced research and development, ensuring that its offerings meet stringent international standards. The company has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its market position as a trusted provider of biopharmaceutical solutions. Through its dedication to innovation and quality, Tot Biopharm continues to make a meaningful impact in the global healthcare landscape.
DitchCarbon Score
How does Tot Biopharm International Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tot Biopharm International Co's score of 21 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tot Biopharm International Co's reported carbon emissions
In 2023, Tot Biopharm International Co, headquartered in China (CN), reported total carbon emissions of approximately 15,812,000 kg CO2e. This figure includes 4,957,000 kg CO2e from Scope 1 emissions and 10,855,000 kg CO2e from Scope 2 emissions. The company has consistently disclosed its emissions data, with a notable reduction in total emissions from 2022, where it reported approximately 11,431,000 kg CO2e. Tot Biopharm has not set specific reduction targets under the Science Based Targets initiative (SBTi) nor does it have documented climate pledges. The absence of Scope 3 emissions data indicates a potential area for future reporting and improvement. The company’s emissions data is sourced directly from its own disclosures, with no cascaded data from parent or related organizations. Overall, Tot Biopharm's commitment to transparency in emissions reporting is evident, although further initiatives and targets could enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 3,562,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 7,757,000 | 0,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Tot Biopharm International Co's Industry?
How Carbon Intensive is Tot Biopharm International Co's Location?
Tot Biopharm International Co's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Tot Biopharm International Co has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
